{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-013490","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.017057+00:00","generated_at":"2026-05-16T03:57:15.336105+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Turn Therapeutics announces presentations at TD Cowen and Oppenheimer healthcare conferences","bullets":["CEO Brad Burnam to present at 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026.","Also presenting virtually at 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.","Company to provide update on Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis.","Updated investor presentation posted on company website on February 9, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-013490","json":"https://secwatch.observer/filing/0001213900-26-013490.json","markdown":"https://secwatch.observer/filing/0001213900-26-013490.md","text":"https://secwatch.observer/filing/0001213900-26-013490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/0001213900-26-013490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/ea0275934-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:57:15.336105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}